Daiichi Sankyo out-licenses cancer candidate DS-6051

18 December 2018

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has entered into a worldwide exclusive license agreement with USA-based AnHeart Therapeutics for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor, currently in Phase I development in the USA and Japan.

While Daiichi Sankyo and AnHeart will collaborate to continue two ongoing Phase I studies, AnHeart will be responsible for further development of DS-6051 worldwide. Daiichi Sankyo will receive an upfront payment and is eligible for clinical, regulatory and sales milestone payments, as well as royalties on worldwide net sales of DS-6051.

Financial terms of the agreement were not disclosed, but Daiichi Sankyo’s shares closed down 1.28% at 3,995 yen today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK